Skip to main content

Recombinant Vaccine Confers More Protection Against Influenza

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 14, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 14, 2023 -- A high-dose recombinant influenza vaccine is more effective than standard-dose vaccine among adults aged 50 to 64 years, according to a study published in the Dec. 14 issue of the New England Journal of Medicine.

Amber Hsiao, Ph.D., M.P.H., from the Kaiser Permanente Vaccine Study Center in Oakland, California, and colleagues conducted a cluster-randomized observational study to compare the effectiveness of recombinant vaccines as compared with standard-dose vaccines against influenza-related outcomes in adults under the age of 65 years. During the 2018 to 2019 and 2019 to 2020 influenza seasons, facilities routinely administered either a high-dose recombinant influenza vaccine (Flublok Quadrivalent) or one of two standard-dose influenza vaccines to adults aged 50 to 64 years and 18 to 49 years.

Data were included for 1,630,328 individuals aged 18 to 64 years who received vaccines (632,962 in the recombinant-vaccine group and 997,366 in the standard-dose group). The researchers identified 1,386 and 2,435 cases of polymerase chain reaction (PCR)-confirmed influenza diagnosed in the recombinant-vaccine and standard-dose groups, respectively. Among participants aged 50 to 64 years, 2.00 and 2.34 cases per 1,000 tested positive for influenza in the recombinant-vaccine and standard-dose groups, respectively (relative vaccine effectiveness, 15.3 percent). The relative vaccine effectiveness against influenza A was 15.7 percent in the same age group. Compared with the standard-dose vaccines, the recombinant vaccine was not significantly more protective against influenza-related hospitalization.

"Participants between the ages of 50 and 64 years who received the recombinant vaccine had more protection against confirmed influenza than those who received a standard-dose vaccine," the authors write.

The study was funded by Sanofi, the manufacturer of the Flublok vaccine.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season

WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...

Preparedness for HPAI A(H5N1) Virus Varies Across Jurisdictions

TUESDAY, May 21, 2024 -- Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses, according to a research letter published...

SARS-CoV-2 Vaccine Does Not Increase New-Onset Seizure Risk

TUESDAY, April 30, 2024 -- There is no risk for new-onset seizure incidence for individuals receiving a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine versus...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.